TY - JOUR
T1 - Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade
AU - Blasco-Fontecilla, Hilario
AU - Baca-Garcia, Enrique
AU - de Leon, Jose
PY - 2010/6
Y1 - 2010/6
N2 - A recent Finnish study reported that long-term cumulative exposure to any antipsychotic treatment was related to lower mortality than was no drug exposure. We hypothesize that the antipsychotic 5-HT2A receptor blockade might protect from ischemic heart disease and buffer the deleterious metabolic effects of antipsychotics. The 5-HT2A receptor may be involved in vascular smooth muscle contraction, coronary artery spasms, platelet aggregation and thrombus formation. 5-HT2A receptor blockade might protect from ischemic heart disease by decreasing platelet aggregation and myocardium hypertrophy. Long-term follow-up studies are needed to clearly establish the long-term contribution of the various antipsychotic drugs to ischemic heart disease, and to explore our hypothesis that 5-HT2A receptor blockade may be protective for cardiovascular disease.
AB - A recent Finnish study reported that long-term cumulative exposure to any antipsychotic treatment was related to lower mortality than was no drug exposure. We hypothesize that the antipsychotic 5-HT2A receptor blockade might protect from ischemic heart disease and buffer the deleterious metabolic effects of antipsychotics. The 5-HT2A receptor may be involved in vascular smooth muscle contraction, coronary artery spasms, platelet aggregation and thrombus formation. 5-HT2A receptor blockade might protect from ischemic heart disease by decreasing platelet aggregation and myocardium hypertrophy. Long-term follow-up studies are needed to clearly establish the long-term contribution of the various antipsychotic drugs to ischemic heart disease, and to explore our hypothesis that 5-HT2A receptor blockade may be protective for cardiovascular disease.
KW - Adverse effects
KW - Antipsychotics
KW - Coronary artery disease
KW - Long QT syndrome
KW - Metabolic syndrome
KW - Mortality
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=77952668659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952668659&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2009.12.005
DO - 10.1016/j.schres.2009.12.005
M3 - Article
C2 - 20053538
AN - SCOPUS:77952668659
SN - 0920-9964
VL - 119
SP - 160
EP - 163
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -